We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bespak | LSE:BPK | London | Ordinary Share | GB0000946276 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 667.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Bespak PLC 24 February 2003 For immediate release: Monday February 24, 2003 Chiesi choose Bespak HFA valve to deliver Budesonide asthma treatment to Europe Bespak (LSE: BPK) today announced details of the latest metered dose inhaler (MDI) valve development and manufacturing partnership with the pharmaceutical company Chiesi Farmaceutici SpA. As part of a long-term project, Bespak is supplying Chiesi with an MDI valve and actuator tailored to its exact requirements for the delivery of Budesonide - an asthma treatment. Chiesi's Budesonide ModuliteTM formulation has been launched on the German market under the brand name BUDIAIRTM. Bespak has been involved in the development of MDI valves for more than three decades and has a breadth of experience that has evolved with the changing needs of the pharmaceutical market. As the drive for chlorofluorocarbon (CFC)-free metered dose inhalers has increased, Bespak has led the way designing a range of valves that are compatible with HFA (ozone friendly) propellants whilst offering similar or improved performance characteristics over their CFC counterparts. "Chiesi screened a number of different valve design options for use in their ModuliteTM formulation and came to the conclusion that Bespak was the partner of choice," said Paolo Chiesi, VP and R&D Director at Chiesi. "The Bespak team got to the heart of Chiesi's HFA needs. Our decision to work together was based on the level of technical support offered by Bespak and the excellence in design and understanding they demonstrated when evaluating our requirements." "Pharmaceutical companies across Europe are working hard to comply with environmental regulations and the phase-out of CFC propellants," said Mark Throdahl, Bespak CEO. "Bespak prides itself on being one of the original champions of the development of HFA valves with the broadest range of marketed product partnerships. We employ a world class team at the forefront of hardware and drug/device interface technology developments. We are able to provide partner companies with substantiated advice and customised delivery solutions." "Chiesi is at the vanguard of the development and commercialisation of HFA formulations in Europe utilising ModuliteTM technology. Beclomethasone HFA is commercialised in several European countries; Budesonide HFA - BUDIAIRTM - is commercialised in Germany and formoterol HFA is in phase III clinical development. The roll out of all our products in Europe and other countries is in progress," said Alberto Chiesi, President and CEO of Chiesi. To support its work in the development of HFA valves and MDIs, Bespak has invested in a multi-million pound building programme at its site in Kings Lynn, UK. Scheduled for completion during 2003, the new state of the art manufacturing facility will extend the company's production capabilities and drive the business forward as a front runner in the development of delivery systems for inhaled therapies. -ENDS- For further information please call: Bespak Plc Tel: +44 (0) 1908 552 600 Mark Throdahl - Chief Executive Buchanan Communications Tel: +44 (0) 20 7466 5000 Nicola How Bespak plc is in the forefront of developing new delivery systems for the pharmaceutical industry. The company has a product range covering metered dose inhalers, dry powder devices, actuator and compliance aids . The company also develops and manufactures drug delivery devices for leading global pharmaceutical companies. The Group has facilities in King's Lynn and Milton Keynes in the UK and in Cary, North Carolina in the USA. Bespak is a public company quoted on the full list of the London Stock Exchange (LSE: BPK). Chiesi Farmaceutici is a European pharmaceutical company, headquartered in Parma, Italy, dedicated to the research, development and commercialization of ethical products, focusing on the respiratory, cardiovascular, muskulo-skeletal & inflammatory, CNS therapeutic areas and on some orphan diseases. Annual Group sales reached 421 million Euro in 2001. The company employs over 2200 people worldwide and has subsidiaries in Italy, France, United Kingdom, Spain, Germany, Austria, Greece, Poland, Hungary, Czech Republic, Slovenia, Slovakia, Brazil, Pakistan and the United States. This information is provided by RNS The company news service from the London Stock Exchange END NRABZLFLXLBZBBK
1 Year Bespak Chart |
1 Month Bespak Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions